In last few years the increasing of population ageing is associated with an increase of incidence of secondary and primary forms of dementia. Alzheimer’s Disease (AD) is the most frequent form of dementia The identification of subjects affected by mild cognitive impairment (MCI) with a high risk of conversion into AD is a very important issue for therapeutic strategies. Aim of our Unit is to identify early markers of disease to achieve the diagnosis in the early stage of AD studying MCI patients using advanced neuroradiological and neurophysiological techniques and repeated neuropsychological evaluations in order to find elements able to distinguish between those who convert and those who do not convert into AD. We are also involved in clinical pharmacological trials to provide to AD patients innovative drugs. Our interest is also focused on the genetic components of AD.